Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pazopanib in advanced endometrial cancer
NL-OMON26478Phase 2Recruiting
- Sponsor
- University Medical Center of Southern Nevada
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in endometrial cancer (EC), sponsored by University Medical Center of Southern Nevada. Primary endpoint: Progression-free rate at 3 months. Started Nov 2011; status: recruiting.
02
Drugs
pazopanib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON26478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26478.